Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

Nature Reviews Rheumatology volume 5, pages 578–582 (2009)Cite this article

Abstract

Cytokines such as tumor necrosis factor (TNF) are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction. TNF was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA). In nearly a decade since anti-TNF agents—such as infliximab, etanercept and adalimumab—were launched as the first biologic therapies to be licensed for RA, much has been learnt about how and when in the disease course this class of drug can be used to achieve optimal therapeutic benefit. Other cytokine targets, such as interleukin (IL)-6 or IL-1, have also been validated and several are in the process of being tested. However, TNF is likely to remain the preferred target of first-line biologic therapy for the foreseeable future as, in populations with active RA despite ongoing, nonbiologic, DMARD therapy, biologic inhibition of either IL-6 or IL-1 demonstrates no obviously superior outcomes to TNF blockade. Furthermore, new approaches to blockade of signaling mediated by bioactive TNF might have the potential to generate higher-magnitude clinical responses than are currently elicited.

Key Points

  • Tumor necrosis factor (TNF) was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA)

  • Combination therapy with an anti-TNF biologic agent plus methotrexate halts progression of joint damage in the majority of patients with RA, irrespective of the extent of destruction on baseline radiography

  • Studies of patients with early RA receiving anti-TNF therapy show particularly favorable outcomes; high proportions of patients achieve sustained low disease activity or remission

  • One of the major pitfalls of biologic TNF inhibition is the occurrence of infectious complications (common or opportunistic)

  • Other shortcomings of current anti-TNF biologics include high costs, inadequate numbers of treated patients achieving sustained, high-magnitude responses or remission and secondary loss of efficacy over time

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The biologic actions of TNF that are known to be relevant in the pathogenesis of RA.

Similar content being viewed by others

References

  1. Brennan, F. M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247 (1989).

    Article  CAS  Google Scholar 

  2. Butler, D. M., Maini, R. N., Feldmann, M. & Brennan, F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-α antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 6, 225–230 (1995).

    CAS  PubMed  Google Scholar 

  3. Haworth, C. et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur. J. Immunol. 21, 2575–2579 (1991).

    Article  CAS  Google Scholar 

  4. Williams, R. O., Feldmann, M. & Maini, R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 89, 9784–9788 (1991).

    Article  Google Scholar 

  5. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594–1602 (2000).

    Article  CAS  Google Scholar 

  6. Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor–Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253–259 (1999).

    Article  CAS  Google Scholar 

  7. Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35–45 (2003).

    Article  CAS  Google Scholar 

  8. Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319–3329 (2008).

    Article  CAS  Google Scholar 

  9. Smolen, J. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797–804 (2009).

    Article  CAS  Google Scholar 

  10. Keystone, E. C. et al. GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann. Rheum. Dis. 68, 789–796 (2009).

    Article  CAS  Google Scholar 

  11. Feldmann, M. & Maini, R. N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9, 1245–1250 (2003).

    Article  CAS  Google Scholar 

  12. Feldmann, M. & Maini, R. N. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163–196 (2001).

    Article  CAS  Google Scholar 

  13. Isaacs, J. D. Antibody engineering to develop new antirheumatic therapies. Arthritis Res. Ther. 11, 225 (2009).

    Article  Google Scholar 

  14. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244–279 (2008).

    Article  CAS  Google Scholar 

  15. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196–2204 (1998).

    Article  CAS  Google Scholar 

  16. Nuki, G., Bresnihan, B., Bear, M. B., McCabe, D. & European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2838–2846 (2002).

    Article  CAS  Google Scholar 

  17. Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614–624 (2002).

    Article  CAS  Google Scholar 

  18. Maini, R. N. et al. Randomised clinical trial of the IL-6 receptor antagonist, tocilizumab (MRA), in rheumatoid arthritis patients with an incomplete response to methotrexate in Europe (CHARISMA). Arthritis Rheum. 54, 2817–2829 (2006).

    Article  CAS  Google Scholar 

  19. Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab In Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum. 58, 2968–2980 (2008).

    Article  CAS  Google Scholar 

  20. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).

    Article  CAS  Google Scholar 

  21. Keystone, E. C. Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr. Opin. Rheumatol. 15, 253–258 (2003).

    Article  CAS  Google Scholar 

  22. Baslund, B. et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52, 2686–2692 (2005).

    Article  CAS  Google Scholar 

  23. Sloan-Lancaster, J., Genovese, M. C., Roberson, S. A. & Van den Bosch, F. Safety, tolerability and evidence of efficacy of intravenous Ly2439821 in patients with rheumatoid arthritis receiving background oral DMARDS. Ann. Rheum. Dis. 68 (Suppl.), 123 (2009).

    Google Scholar 

  24. Durez, P. et al. AIN457 An anti-IL17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof of concept study. Ann. Rheum. Dis. 68 (Suppl.), 125 (2009).

    Google Scholar 

  25. Dayer, J. M., Beutler, B. & Cerami, A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162, 2163–2168 (1985).

    Article  CAS  Google Scholar 

  26. Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D. & Mundy, G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516–518 (1986).

    Article  CAS  Google Scholar 

  27. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–4031 (1991).

    Article  CAS  Google Scholar 

  28. Iwamoto, S. et al. TNF-α drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking TH1 and TH17 responses. J. Immunol. 179, 1449–1457 (2007).

    Article  CAS  Google Scholar 

  29. Notley, C. A. et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for TH1 and TH17 cells. J. Exp. Med. 205, 2491–2497 (2008).

    Article  CAS  Google Scholar 

  30. Breedveld, F. C. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

    Article  CAS  Google Scholar 

  31. Klareskog, L. et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).

    Article  CAS  Google Scholar 

  32. Smolen, J. S. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006).

    Article  CAS  Google Scholar 

  33. Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68, 823–827 (2009).

    Article  CAS  Google Scholar 

  34. St Clair, E. W. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50, 3432–3443 (2004).

    Article  CAS  Google Scholar 

  35. Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375–382 (2008).

    Article  CAS  Google Scholar 

  36. Hjardem, E. et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor α inhibitor? Ann. Rheum. Dis. 66, 1184–1189 (2007).

    Article  CAS  Google Scholar 

  37. Hyrich, K. L. et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56, 13–20 (2007).

    Article  CAS  Google Scholar 

  38. Smolen, J. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009).

    Article  CAS  Google Scholar 

  39. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008).

    Article  CAS  Google Scholar 

  40. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor-α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).

    Article  CAS  Google Scholar 

  41. Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793–2806 (2006).

    Article  CAS  Google Scholar 

  42. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).

    Article  CAS  Google Scholar 

  43. Keane, J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44, 714–720 (2005).

    Article  CAS  Google Scholar 

  44. Askling, J. & Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 138–144 (2008).

    Article  CAS  Google Scholar 

  45. Brennan, A. et al. Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46, 1345–1354 (2007).

    Article  CAS  Google Scholar 

  46. Bejarano, V. et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 59, 1467–1474 (2008).

    Article  Google Scholar 

  47. Augustsson, J., Neovius, M., Cullinane-Carli, C., Eksborg, S. & van Vollenhoven, R. F. Rheumatoid arthritis (RA) patients treated with TNF-antagonists increase their participation in the work-force—potential for significant long-term indirect cost gains. Data from a population-based registry. Ann. Rheum. Dis. doi:ard.2009.108035v1.

  48. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412–1419 (2004).

    Article  CAS  Google Scholar 

  49. Weinblatt, M. et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann. Rheum. Dis. 66, 228–234 (2007).

    Article  CAS  Google Scholar 

  50. Dembic, Z. et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2, 231–237 (1990).

    Article  CAS  Google Scholar 

  51. Naume, B., Shalaby, R., Lesslauer, W. & Espevik, T. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J. Immunol. 146, 3045–3048 (1991).

    CAS  PubMed  Google Scholar 

  52. Erikstein, B. K. et al. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur. J. Immunol. 21, 1033–1037 (1991).

    Article  CAS  Google Scholar 

  53. Ware, C. F. et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes: differential regulation of the type I TNF receptor during activation of resting and effector T cells. J. Immunol. 147, 4229–4238 (1991).

    CAS  PubMed  Google Scholar 

  54. Konttinen, Y. T. et al. Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res. 2, 348–355 (2000).

    Article  CAS  Google Scholar 

  55. Kassiotis, G. & Kollias, G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193, 427–434 (2001).

    Article  CAS  Google Scholar 

  56. Eugster, H. P. et al. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 29, 626–632 (1991).

    Article  Google Scholar 

  57. Mori, L., Iselin, S., De Libero, G. & Lesslauer, W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157, 3178–3182 (1996).

    CAS  PubMed  Google Scholar 

  58. Williams-Skipp, C. et al. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum. 60, 408–418 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kennedy Institute of Rheumatology Division, Imperial College, London, UK

    Peter C. Taylor & Marc Feldmann

Authors
  1. Peter C. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Feldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter C. Taylor.

Ethics declarations

Competing interests

Peter C. Taylor declares that he has been involved in speakers' bureaux (honoraria) and acted as a consultant for UCB, Bristol-Myers Squibb, Roche, Centocor JNJ, Schering-Plough, Wyeth and Abbott.

Marcus Feldmann declares that he has acted as a consultant for Abbott; has acted as a consultant for, received grant or research support from, is a shareholder in, and a holds a patent from Centocor JNJ; has acted as a consultant for, and received grant or research support from, Wyeth; has acted as a consultant for, and is a shareholder in, Schering-Plough, has acted as a consultant for Amgen; has acted as a consultant for, and received grant or research support from, Roche; and has acted as a consultant for UCB.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, P., Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5, 578–582 (2009). https://doi.org/10.1038/nrrheum.2009.181

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.181

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing